This protocol covers first-line management of diffuse astrocytoma — specifically the IDH-mutant, 1p19q non-codeleted, CNS WHO grade 2 subtype (low-grade diffuse glioma). It provides a structured, evidence-graded approach to initial treatment selection.
Current evidence supports a combined modality approach involving radiation therapy together with adjuvant chemotherapy. The specific agent selection, regimen structure, and sequencing are detailed in the full protocol.